Income Statement (TTM)
N4 Pharma Plc Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
|
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 99.90 | 100.00 | 50.00 | 12.14 | 10.84 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | ||||||
| Change (%) | ||||||
| % of Revenue | ||||||
| Gross Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 99.90 | 100.00 | 50.00 | 12.14 | 10.84 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 1 | 1 | 1 | 1 | 1 | 1 |
| Change (%) | -0.83 | -5.04 | -5.31 | 14.90 | 12.97 | |
| % of Revenue | 74,102.97 | 36,762.93 | 17,455.30 | 11,019.42 | 11,290.90 | 11,507.77 |
| R&D | 0 | 1 | 1 | 1 | 0 | 0 |
| Change (%) | 26.65 | -6.34 | -6.77 | -13.91 | -16.15 | |
| % of Revenue | 50,057.83 | 31,714.90 | 14,851.31 | 9,230.11 | 7,086.61 | 5,360.99 |
| OpEx | 1 | 1 | 1 | 1 | 1 | 1 |
| Change (%) | 10.25 | -5.64 | -5.98 | 1.77 | 1.74 | |
| % of Revenue | 124,160.80 | 68,477.83 | 32,306.61 | 20,249.53 | 18,377.50 | 16,868.76 |
| Operating Income | -1 | -1 | -1 | -1 | -1 | -1 |
| Change (%) | 10.18 | -5.80 | -6.15 | 1.72 | 1.69 | |
| % of Revenue | -124,060.90 | -68,377.83 | -32,206.61 | -20,149.53 | -18,277.49 | -16,768.76 |
| Interest Expense | -0 | -0 | -0 | -0 | ||
| Change (%) | 99.52 | -0.00 | ||||
| % of Revenue | -59.16 | -5.30 | -7.05 | -6.29 | ||
| Net Income | -1 | -1 | -1 | -1 | -1 | -1 |
| Change (%) | 15.68 | -7.53 | -8.15 | -0.90 | -0.91 | |
| % of Revenue | -112,315.25 | -64,993.91 | -30,048.39 | -18,399.86 | -16,260.79 | -14,537.52 |
Source: Capital IQ
